Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer
Status:
Terminated
Trial end date:
2018-05-23
Target enrollment:
Participant gender:
Summary
The goal of this study is to determine if co-administration of metformin and doxorubicin in
breast cancer patients receiving neoadjuvant or adjuvant therapy will reduce the number of
patients who develop a significant change in left ventricle ejection fraction (LVEF).
Phase:
Phase 2
Details
Lead Sponsor:
Avera McKennan Hospital & University Health Center